Live Webinar

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Hosted by AJMC and Targeted Oncology

-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Logo Image
|Peer-Reviewed|December 23, 2020

Evidence-Based Oncology

  • January 2021
  • Volume 27
  • Issue 1

Supplemental Material: Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

Supplemental materials for article examining the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.

eAPPENDIX Chemotherapy-Induced Peripheral Neuropathy in mBC

Articles in this issue

over 5 years ago

ASH 2020: Clinical Updates

over 5 years ago

ASH 2020: COVID-19 and Hematology

over 5 years ago

ASH 2020: CAR T-Cell Therapy Updates

over 5 years ago

ASH 2020: The Next Wave

over 5 years ago

2020 SABCS: Topics in Precision Oncology

over 5 years ago

Lauren M. Corduck, Founder of Oneinforty, Dies at 49; Advocated for Change in BRCA Testing Guidelines

over 5 years ago

Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel

over 5 years ago

Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

over 5 years ago

Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer

Related Content